PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.34 - 0.34
0.23 - 0.41
110.0K / 51.2K (Avg.)
-1.33 | -0.26
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-36.92%
Negative revenue growth while 8198.HK stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-28.71%
Negative gross profit growth while 8198.HK is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
41.46%
EBIT growth of 41.46% while 8198.HK is zero. Bruce Berkowitz would see if small gains can be scaled further.
36.37%
Operating income growth of 36.37% while 8198.HK is zero. Bruce Berkowitz would see if this modest edge can become significant.
33.37%
Net income growth of 33.37% while 8198.HK is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
34.60%
EPS growth of 34.60% while 8198.HK is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
34.60%
Diluted EPS growth of 34.60% while 8198.HK is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-0.00%
Share reduction while 8198.HK is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.14%
Negative OCF growth while 8198.HK is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-34.72%
Negative FCF growth while 8198.HK is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-95.52%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-87.79%
Negative 5Y CAGR while 8198.HK stands at 49.96%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-53.53%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-152.98%
Negative 10Y OCF/share CAGR while 8198.HK stands at 12.73%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
63.76%
5Y OCF/share CAGR at 50-75% of 8198.HK's 109.32%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-0.65%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-298.63%
Negative 10Y net income/share CAGR while 8198.HK is at 91.32%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-439.52%
Negative 5Y net income/share CAGR while 8198.HK is 91.45%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-39.06%
Negative 3Y CAGR while 8198.HK is 91.92%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-46.65%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-47.97%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-45.59%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
-100.00%
Cut dividends over 10 years while 8198.HK stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Negative 5Y dividend/share CAGR while 8198.HK stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.45%
Negative asset growth while 8198.HK invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.52%
We have a declining book value while 8198.HK shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-20.31%
We’re deleveraging while 8198.HK stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-69.33%
Our R&D shrinks while 8198.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-29.69%
We cut SG&A while 8198.HK invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.